title: Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer.
abstract: Whether the human papillomavirus (HPV) status of the tumor affects the sensitivity to neoadjuvant chemotherapy, and the prognosis in advanced uterine cervical cancer (FIGO stage III or higher) remains unknown. We examined the HPV status of 43 patients who had received CDDP therapy by balloon-occluded arterial infusion (BOAI), as neoadjuvant chemotherapy for advanced uterine cervical cancer (squamous cell carcinoma) stage III or higher. DNA was extracted from formalin-fixed, paraffin-embedded tumor samples obtained by punch biopsy before the neoadjuvant chemotherapy. The detection of HPV and its typing were analyzed by a polymerase chain reaction (PCR)-based assay using consensus primers for the L1 consensus regions. HPV DNA was detected in all 43 patients (100%): 29 cases with HPV 16 (67.4%), 5 cases with HPV 33 (11.6%), 4 cases with HPV 31 (9.3%), 3 cases with HPV 35 (7.0%), 1 case with HPV 18 (2.3%) and 1 case with HPV 58 (2.3%). The HPV types were divided into 3 groups, HPV 16, HPV 33 and other HPV types (HPV 18, 31, 35, 58), and comparisons and examinations were performed among the 3 groups. Although the rates of tumor reduction and operation accomplishment after 3 courses of BOAI showed no significant differences among the 3 groups, there were significant differences in the survival rates. The survival rate of advanced uterine cervical cancer patients with HPV 33 infection was the highest, followed by that of patients with HPV 16 infection. The survival rates of patients with the other types of HPV infection were the worst among the 3 groups and significantly lower than those of patients with HPV 16 or HPV 33 infection. The differences in the curative effect after BOAI may depend on the different characters of the HPV types.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nobeyama
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sumi
authors.forename: Fumiko
authors.initials: F
authors.lastname: Misugi
authors.forename: Eri
authors.initials: E
authors.lastname: Okamoto
authors.forename: Kanae
authors.initials: K
authors.lastname: Hattori
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Yasui
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Honda
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwai
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishiko
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis*; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004279:DNA, Viral; D002945:Cisplatin